Allogene Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ALLO Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
09 Dec 24	SellUS$19,916	Deborah Messemer	Individual	9,136	US$2.18
05 Dec 24	SellUS$19,917	Franz Humer	Individual	9,221	US$2.16
30 May 24	SellUS$26,181	Franz Humer	Individual	11,200	US$2.34
16 May 24	BuyUS$4,999,997	Vida Ventures Advisors, LLC	Company	1,724,137	US$2.90
30 Jan 24	BuyUS$683	Geoffrey Parker	Individual	190	US$3.60

Insider Trading Volume

Insider Buying: ALLO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ALLO?
Owner Type	Number of Shares	Ownership Percentage
General Public	4,505,754	2.15%
Individual Insiders	17,034,762	8.12%
VC/PE Firms	18,716,306	8.93%
Public Companies	22,032,040	10.5%
Institutions	147,383,229	70.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.6%.

Top Shareholders

Top 25 shareholders own 85.59% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14.3%	FMR LLC	30,026,956	US$56.2m	-3.94%	no data
10.5%	Pfizer Inc.	22,032,040	US$41.2m	0%	no data
8.93%	TPG Capital, L.P.	18,716,306	US$35.0m	0%	0.09%
8.48%	BlackRock, Inc.	17,772,745	US$33.2m	8.07%	no data
3.97%	The Vanguard Group, Inc.	8,327,699	US$15.6m	1.61%	no data
3.68%	David Chang	7,723,302	US$14.4m	0%	no data
3.34%	State Street Global Advisors, Inc.	7,013,083	US$13.1m	-8.54%	no data
3.29%	Capital Research and Management Company	6,896,552	US$12.9m	0%	no data
2.96%	Lynx1 Capital Management LP	6,202,374	US$11.6m	178%	4.85%
2.92%	Arie Belldegrun	6,129,941	US$11.5m	0%	no data
2.7%	PRIMECAP Management Company	5,668,260	US$10.6m	-0.03%	0.01%
2.4%	Citadel Advisors LLC	5,039,594	US$9.4m	106%	0.01%
2.31%	T. Rowe Price Group, Inc.	4,838,743	US$9.0m	-16.4%	no data
2.08%	Woodline Partners LP	4,364,300	US$8.2m	0.12%	0.07%
1.87%	JP Morgan Asset Management	3,918,791	US$7.3m	-1.04%	no data
1.54%	Geode Capital Management, LLC	3,227,104	US$6.0m	14.4%	no data
1.39%	Wildcat Capital Management, LLC	2,920,787	US$5.5m	0%	2.36%
1.37%	Frazier Life Sciences Management, LP	2,867,750	US$5.4m	0%	0.21%
1.33%	Two Sigma Investments, LP	2,797,970	US$5.2m	-5.5%	0.01%
1.3%	Dimensional Fund Advisors LP	2,730,480	US$5.1m	7.05%	no data
1.3%	Perceptive Advisors LLC	2,725,000	US$5.1m	0%	0.12%
1.15%	Two Sigma Advisers, LP	2,410,400	US$4.5m	7.49%	0.01%
0.86%	Vida Ventures Advisors, LLC	1,798,163	US$3.4m	0%	2.12%
0.8%	Goldman Sachs Group, Investment Banking and Securities Investments	1,672,190	US$3.1m	52.9%	no data
0.78%	ExodusPoint Capital Management, LP	1,634,838	US$3.1m	462%	0.03%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 04:08
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Allogene Therapeutics, Inc. is covered by 34 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Allen	Baird
Shanshan Xu	Berenberg
Jason Matthew Gerberry	BofA Global Research